[1] Anderson JL, Halperin JL, Albert NM, et al. Management of patients with atrial fibrillation (compilation of 2006 ACCF/AHA/ESC and 2011 ACCF/AHA/HRS recommendations): a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines[J]. J Am Coll Cardiol, 2013, 61(18):1935-1944.[2] Jiang MH, Su YM, Tang JZ, et al. Angiotensinconverting enzyme gene 2350 G/A polymorphism and susceptibility to atrial fibrillation in Han Chinese patients with essential hypertension[J]. Clinics(Sao Paulo), 2013, 68(11):1428-1432.[3] Camm AJ, Lip GY, De Caterina R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association[J]. Eur Heart J, 2012, 33(21):2719-2747.[4] Pan M, Zhu JH, Jiang WP, et al. Inflammation: a possible pathogenic link to atrial fibrillation[J]. Med Hypotheses, 2006, 67(6):1305-1307.[5] Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)[J]. Eur Heart J, 2010, 31(19):2369-2429.[6] Hu D, Sun Y. Epidemiology, risk factors for stroke, and management of atrial fibrillation in China[J]. J Am Coll Cardiol, 2008, 52(10):865-868.[7] Toutouzas K, Synetos A, Drakopoulou M, et al. The role of inflammation in atrial fibrillation: a myth or a fact?[J]. Am J Med Sci, 2009, 338(6):494-499.[8] 郑金国, 邓新桃, 何永辉, 等. 心房颤动与白细胞介素-6的关系[J]. 江苏大学学报:医学版, 2010, 20(5):425-427.[9] 陈楚, 魏美芳, 潘闽. 肿瘤坏死因子α与心房颤动及左心房重构的关系[J]. 南通大学学报:医学版, 2012, 32(3):185-187.[10] Bruins P, te Velthuis H, Yazdanbakhsh AP, et al. Activation of the complement system during and after cardiopulmonary bypass surgery: postsurgery activation involves Creactive protein and is associated with postoperative arrhythmia[J]. Circulation, 1997, 96(10):3542-3548.[11] Frustaci A, Chimenti C, Bellocci F, et al. Histological substrate of atrial biopsies in patients with lone atrial fibrillation[J]. Circulation, 1997, 96(4):1180-1184.[12] Yamashita T, Sekiguchi A, Iwasaki YK, et al. Recruitment of immune cells across atrial endocardium in human atrial fibrillation[J]. Circ J, 2010,74(2):262-270.[13] Aviles RJ, Martin DO, AppersonHansen C, et al. Inflammation as a risk factor for atrial fibrillation[J]. Circulation, 2003, 108(24):3006-3010.[14] Sata N, Hamada N, Horinouchi T, et al. Creactive protein and atrial fibrillation. Is inflammation a consequence or a cause of atrial fibrillation?[J]. Jpn Heart J, 2004, 45(3):441-445.[15] Gedikli O, Dogan A, Altuntas I, et al. Inflammatory markers according to types of atrial fibrillation[J]. Int J Cardiol, 2007, 120(2):193-197.[16] Marcus GM, Smith LM, Ordovas K, et al. Intracardiac and extracardiac markers of inflammation during atrial fibrillation[J]. Heart Rhythm, 2010, 7(2):149-154.[17] Li J, Song J, Jiang MH, et al. Interleukin6 promoter polymorphisms and susceptibility to atrial fibrillation in elderly Han Chinese patients with essential hypertension[J]. J Interferon Cytokine Res, 2012, 32(11):542-547.[18] Alegret JM, Aragonès G, Elosua R, et al. The relevance of the association between inflammation and atrial fibrillation[J]. Eur J Clin Invest, 2013, 43(4):324-331.[19] Hagiwara N. Inflammation and atrial fibrillation[J]. Circ J, 2010, 74(2):246-247.[20] Gao SP, Deng XT, Ge LJ, et al. Is inflammation linked to thrombogenesis in atrial fibrillation?[J]. Int J Cardiol, 2011, 149(2):260-261.[21] Deng XT, Jiang MH, Zhu JH, et al. The association of interleukin 6634C/G polymorphism with left atrial thrombus and severe spontaneous echocontrast in patients with atrial fibrillation[J]. Clin Appl Thromb Hemost, 2013, 19(6):673-678.[22] Tsioufis C, Syrseloudis D, Hatziyianni A, et al. Relationships of CRP and P wave dispersion with atrial fibrillation in hypertensive subjects[J]. Am J Hypertens, 2010, 23(2):202-207.[23] Mazza A, Bendini MG, Cristofori M, et al. Creactive protein and Pwave in hypertensive patients after conversion of atrial fibrillation[J]. J Cardiovasc Med (Hagerstown), 2013, 14(7):520-527.[24] Kourliouros A, Savelieva I, Kiotsekoglou A, et al. Current concepts in the pathogenesis of atrial fibrillation[J]. Am Heart J, 2009, 157(2):243-252.[25] Lappega。rd KT, Hovland A, Pop GA, et al. Atrial fibrillation: inflammation in disguise?[J]. Scand J Immunol, 2013, 78(2):112-119.[26] Fauchier L, Pierre B, de Labriolle A, et al. Antiarrhythmic effect of statin therapy and atrial fibrillation a metaanalysis of randomized controlled trials[J]. J Am Coll Cardiol, 2008, 51(8):828-835.[27] Hung CY, Lin CH, Loh elW, et al. CHADS(2) score, statin therapy, and risks of atrial fibrillation[J]. Am J Med, 2013, 126(2):133-140.[28] Baran C,, Durdu S, Dalva K, et al. Effects of preoperative short term use of atorvastatin on endothelial progenitor cells after coronary surgery: a randomized, controlled trial[J]. Stem Cell Rev, 2012, 8(3):963-971.[29] Maggioni AP, Fabbri G, Lucci D, et al. Effects of rosuvastatin on atrial fibrillation occurrence: ancillary results of the GISSIHF trial[J]. Eur Heart J, 2009, 30(19):2327-2336.[30] Vermes E, Tardif JC, Bourassa MG, et al. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials[J]. Circulation, 2003,107(23):2926-2931.[31] Kuhn EW, Liakopoulos OJ, Borys MJ, et al. Statins improve surgical ablation outcomes for atrial fibrillation in patients undergoing concomitant cardiac surgery[J]. Interact Cardiovasc Thorac Surg, 2010, 11(1):24-28.[32] GISSIAF Investigators, Disertori M, Latini R, et al. Valsartan for prevention of recurrent atrial fibrillation[J]. N Engl J Med, 2009, 360(16):1606-1617.[33] Goldstein RN, Ryu K, Khrestian C, et al. Prednisone prevents inducible atrial flutter in the canine sterile pericarditis model[J]. J Cardiovasc Electrophysiol, 2008, 19(1):74-81.[34] Dernellis J, Panaretou M. Relationship between Creactive protein concentrations during glucocorticoid therapy and recurrent atrial fibrillation[J]. Eur Heart J, 2004, 25(13):1100-1107. |